More recent work in engineering, physics, biology, and other areas has shown the ubiquity of fractals throughout nature.
This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.
Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti TNF-α).
With the recent engineering of more sensitive AChE enzymes, the development of more reliable immobilization matrices and the progress in the area of microelectronics, AChE biosensors could become competitive for multi-analyte screening and soon be used for the development of portable instrumentation for rapid toxicity testing of samples.
This paper presents a methodology, which draws upon traditional organisational theory and combines it with the more recent business process re-engineering approaches, for the analysis of organisational issues in a CE environment.
Their applications in civil engineering are more recent than those with Fibre Reinforced Polymers (FRP) employing carbon, glass or aramid textiles, and their mechanical properties still need to be deeply investigated.
More recent studies have used genomic engineering to compare endogenous versus mutated regulatory elements.
A more recent development has involved the engineering of CIRs to incorporate multiple signalling domains.
However, more recent studies have focused up engineering the antigen-specific TCRs in order to prevent pairing with endogenous TCR genes (Willemsen et al, 2000).
Furthermore, we consider more recent aspects of T cell specificity engineering.
